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Eﬃcacy of short-course therapy with cephalosporins for treatment of group A β-hemolytic streptococcus (GABHS) pharyngitis is
still controversial. Subjects were 226 children with a history of at least one episode of GABHS pharyngitis. Recurrence within the
follow-up period (3 weeks after initiation of therapy) occurred in 7 of the 77 children in the 5-day treatment group and in 1 of the
149 children in the 10-day treatment group; the incidence of recurrence being signiﬁcantly higher in the 5-day treatment group.
Bacteriologic treatment failure (GABHS isolation without overt pharyngitis) at follow-up culture was observed in 7 of the 77
children in the 5-day treatment group and 17 of the 149 children in the 10-day treatment group. There was no statistical diﬀerence
between the two groups. A 5-day course of oral cephalosporins is not always recommended for treatment of GABHS pharyngitis
in children who have repeated episodes of pharyngitis.
Copyright © 2009 Hideaki Kikuta et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Group A β-hemolytic streptococci (GABHS, also referred to
as Streptococcus pyogenes) are the most common bacterial
cause of acute pharyngitis, accounting for approximately
15 to 30% of cases in children and 5 to 10% of cases
in adults [1–3]. The objectives of treatment for GABHS
pharyngitis are prevention of rheumatic fever, prevention
of suppurative complications, reduction in transmission of
GABHS, and shortening of the clinical course. Although the
standard oral recommended therapy for GABHS pharyngitis
has long been penicillin V for 10 days, there has been no
change in the susceptibility of GABHS for over 50 years [1–
4]. However, recurrent GABHS infections occurred more
frequently in the 1990s than the 1970s, and treatment
failure rates as high as 10 to 30% have been reported
[5, 6]. Reasons for failure of the standard therapy include
an increase in β-lactamase-producing pharyngeal pathogens
that inactivate penicillin, poor compliance, intracellular
location of GABHS, eradication of protective pharyngeal α-
streptococci, and increased exposure in crowded day-care
centers and schools [7–9].
The increase in failure rate of the standard 10-day
course of therapy with penicillin has heightened interest
in alternative treatments for this infection. Cephalosporins
have been used successfully for treatment of this infection
since the 1970s [10, 11]. A meta-analysis showed that 10-
day cephalosporin treatment was superior in eradication
of GABHS and in clinical response [12]. Recent studies
on the eﬃcacy of a short-course treatment (5 days) with
cephalosporins compared with that of 10-day penicillin
V treatment have shown that the shorter cephalosporin
treatments were equivalent or superior in eradication of
GABHSandinclinicalresponse[13].However,therearesev-
eral controversial issues regarding the increase in recurrent
GABHS pharyngitis since the 1990s, reasons for failure of
the standard penicillin therapy and evaluation of alternative
cephalosporin treatments for GABHS pharyngitis [14–16].
The purpose of this study was to determine the eﬃcacy of
a 5-day course of oral cephalosporin compared with that of2 International Journal of Pediatrics
a 10-day course of oral cephalosporin for recurrent GABHS
pharyngitis in children.
2.MaterialsandMethods
2.1. Subjects. In a prospective, multicenter surveillance
study, a total of 299 children with a history of at least
1 episode of GABHS pharyngitis were enrolled at private
oﬃces of 41 practicing pediatricians and hospitals of 23
practicing pediatricians between May 2006 and August 2007
in Hokkaido, the northernmost island of Japan. A total
of 73 children were excluded after enrollment because of
incomplete follow-up (n = 61), inappropriate enrollment
(n = 11), and noncompliance (n = 1). The number of
eligible patients for the study was 226. The 226 children
(138 males and 88 females; 2 to 14 years old; mean
age: 6.8 years; SD: 2.0 years) were diagnosed as having
GABHS pharingitis by both clinical ﬁndings and a positive
reaction in pharyngeal swab specimens using commercially
available rapid antigen detection tests (RADTs) for GABHS
(Immunocard ST Strep A, TFB, INC., Tokyo; Dipstick Eiken
Strept A, Eiken Chemical Co., Ltd., Tokyo; Quickview Strep
A, Wako Pure Chemical Industries, Ltd., Osaka). The clinical
ﬁndings included presence of oropharyngeal erythema or
tonsillar exudate, fever, cervical lymphadenitis, and sore
throat. Patients with signs and symptoms suggestive of viral
infection (rhinorrhea, cough, conjunctivitis) were excluded.
Follow-up visit and follow-up culture were scheduled 3
weeks after the initiation of therapy. The culture samples
were obtained by rubbing over the posterior portion of the
pharynx and both tonsils with a sterile, rayon-tipped swab.
Allpharyngealswabspecimenswerecollectedafterobtaining
informed consent from the patients or children’s parents.
The swabs were placed in an aerobic transport system
and then transported to our laboratory. The children with
subsequent GABHS pharyngitis within the follow-up period
were also diagnosed by both clinical ﬁndings and results
of RADTs. The 226 patients were treated with cefditoren
pivoxil (9mg/kg; maximum dose of 300mg/day, 3 times a
day) for 5 days (77 patients) or for 10 days (149 patients).
Since each pediatrician arbitrarily decided the period of
antibiotic treatment, there was no complete randomization
of the patients.
2.2. Deﬁnition. Clinical response to treatment was deﬁned
here as recurrence (clinical treatment failure; clinically and
RADT-conﬁrmed GABHS pharyngitis within the follow-
up period, irrespective of T serotype) and as clinical cure
(clinical treatment success; no clinical ﬁndings of GABHS
pharyngitis within the follow-up period). Bacteriologic
response to treatment was deﬁned here as eradication (bac-
teriologic treatment success; no GABHS isolation at follow-
up visit) and as noneradication (bacteriologic treatment
failure;GABHSisolationwithoutovertpharyngitisatfollow-
up visit, irrespective of T serotype). Treatment success was,
therefore, deﬁned as bacteriologic treatment success with
no recurrence, and treatment failure was deﬁned as either
clinical or bacteriologic treatment failure.
2.3. Serotyping. Serotyping was examined for T types by
the agglutination method using Group A streptococcus
hemolyticus T typing immunoserum “SEIKEN” (Denka
Seiken Co., Ltd., Tokyo).
2.4. Statistical Analysis. Quantitative variables were com-
pared using Welch’s t-test, and qualitative variables were
compared using the chi-square test with Fisher’s exact test.
For all statistical comparisons, P<. 05 was considered to be
signiﬁcant.
3. Results and Discussion
3.1. Results. The characteristics of children with repeated
GABHApharyngitisareshowninTable 1.Themeannumber
of episodes of repeated GABHS pharyngitis including the
present episode was 2.79 (range: 2–12; SD: 1.35). Of the 226
patients, 182 (80.5%) patients had a history of at least 2
episodes of repeated GABHS pharyngitis. The mean interval
between preceding and present episodes was 10.48 months
(range: 0.4–79 months; SD: 13.85). Of the 226 patients, 98
(43.3%) patients had preceding GABHS pharyngitis within
3 months before the present GABHS pharyngitis. The mean
length of follow-up excluding recurrence cases (deﬁnition
of recurrence case given below) was 22.20 days (range: 14–
35 days; SD: 2.98 days). Of the 226 patients, 218 (96.4%)
patients were followed up for 14–28 days after the initiation
of therapy. The characteristics of children treated for 5 days
and 10 days are shown in Table 1. The ratios of males to
females were 1 : 0.67 in the 5-day treatment group and
1:0 .62 in the 10-day treatment group. Mean ages were
6.70 years (range: 3–12 years; SD: 1.93 years) in the 5-day
treatment group and 6.80 years (range: 2–14 years; SD: 2.10
years) in the 10-day treatment group. Mean numbers of
episodes of repeated GABHS pharyngitis were 2.75 (range:
2–12; SD: 1.54) in the 5-day treatment group and 2.81
(range: 2–8; SD: 1.24) in the 10-day treatment group. Mean
intervals between preceding and present episodes were 12.95
months (range: 0.5–79 months; SD: 17.30 months) in the
5-day treatment group and 9.20 months (range: 0.4–55
months; SD: 11.47 months) in the 10-day treatment group.
Mean lengths of follow-up excluding recurrence cases were
22.57 days (range: 14–32 days; SD: 3.03 days) in the 5-
day treatment group and 22.02 days (range: 15–35 days;
SD: 2.94 days) in the 10-day treatment group. There were
no signiﬁcant diﬀerences between the two treatment groups
in the distribution of age, gender, number of episodes of
repeated GABHS pharyngitis, interval between preceding
and present episodes, and length of follow-up.
The clinical and bacteriological results are shown in
Table 2. Recurrence (clinical treatment failure) occurred in
7 (9.1%) of the 77 children in the 5-day treatment group
and in 1 (0.7%) of the 149 children in the 10-day treatment
group. The 5-day treatment group showed a signiﬁcantly
higher incidence of recurrent GABHS pharyngitis than that
in the 10-day treatment group (P = .003). The eight
patients with recurrent GABHS phayryngitis included 5
males and 3 females with a mean age of 6.36 years (range:International Journal of Pediatrics 3
Table 1: Characteristics of children with repeated GABHA pharyngitis.
Characteristics Total 5-day treatment group 10-day treatment group P value
Number of cases 226 77 149
Male:Female 138 : 88 46 : 31 92 : 57 .775
Age (years) (mean±SD) 6.77 ±2.04 6.70 ±1.93 6.80 ±2.10 .728
Frequency of episodes (times) (mean±SD) 2.79 ±1.35 2.75 ±1.54 2.81 ±1.24 .768
Interval between preceding and present
episodes (months) (mean±SD)
10.48 ±13.81 2 .95 ±17.30 9.20 ±11.47 .089
Length of follow-up (days) (mean±SD) 22.20 ±2.98 22.57 ±3.03 22.02 ±2.94 .203
5–8 years; SD: 0.91 years). The mean interval from onset of
the index infection to onset of subsequent recurrent GABHS
pharyngitis was 11.3 days after the initiation of therapy
(range: 6–22 days; SD: 4.94 days). The mean number of
episodes of repeated GABHS pharyngitis was 2.88 (range:
2–6; SD: 1.36). The mean interval between preceding and
present episodes was 10.81 months (range: 0.5–24 months;
SD: 8.268 months). There was no recognizable risk factor
of recurrent GABHS pharyngitis in the patients, probably
due to the limited number of recurrent cases. Bacteriologic
treatment failure at the follow-up visit was observed in 7
(9.1%) of the 77 children in 5-day treatment group and
in 17 (11.4%) of the 149 children in the 10-day treatment
group. There was no signiﬁcant diﬀerence between the two
treatment groups (P = .655). The treatment failure rates
were 18.2% in the 5-day group and 12.1% in the 10-day
group. This diﬀerence was also not statistically signiﬁcant
(P = .231). No poststreptococcal sequelae were noted in this
study.
The characteristics of children in the treatment success
group (bacteriologic treatment success with no recurrence)
and treatment failure group (either clinical or bacteriologic
treatment failure) are shown in Table 3. Ratios of males to
f e m a l e sw e r e1:0 .73 in the treatment success group (194
children) and 1 : 0.23 in the treatment failure group (32
children). Treatment failure rates were signiﬁcantly aﬀected
by gender (P = .011). Mean ages were 6.86 years (range:
2–14 years; SD: 2.12 years) in the treatment success group
and 6.24 years (range: 3–9 years; SD: 1.39 years) in the
treatment failure group (P = .036). Treatment failure was
observed more frequently in the 86 children aged 6 to 7 years
(in 22 of the 86 children, treatment failure rate of 25.6%)
than in the 66 children aged 2 to 5 years (in 6 of the 66
children, treatment failure rate of 9.1%; P<. 001) and in
the 74 children aged 8 to 14 years (in 4 of the 74 children,
treatment failure rate of 5.4%; P<. 001). The mean number
of episodes of repeated GABHS pharyngitis in the treatment
success group was 2.77 (range: 2–6; SD: 1.36) and that in
the treatment failure group was 2.91 (range: 2–12; SD: 1.26),
the diﬀerence between the groups not being statistically
signiﬁcant(P = .586).Themeanintervalsbetweenpreceding
and present episodes were 11.04 months (range: 0.5–79
months; SD: 14.57 months) in the treatment success group
and7.05months(range:0.4–27months;SD:7.31months)in
the treatment failure group. Although the diﬀerence between
the intervals in the two groups was statistically signiﬁcant
(P = .019), the interval responsible for treatment failure
could not be statistically determined.
All corresponding strains isolated from the 24 children
with positive follow-up cultures both at pre- and posttreat-
ments had the same serotype. Six diﬀerent T types were
identiﬁed, of which T12 was the most common serotype. In
the 8 children with recurrence within the follow-up period,
only 4 corresponding strains isolated at pretreatment and at
recurrence were available for characterization by serotyping.
GABHS with diﬀerent serotype was identiﬁed in one child in
the 5-day treatment group but not in other children.
3.2. Discussion. Recurrence of GABHS pharyngitis fre-
quently occurs in children after treatment. Approximately
10 to 20% of children have recurrent infection within 1
year of an index infection [5, 11, 17]. Possible explanations
for the recurrence are 1) reinfection: new infection with
GABHS, and 2) relapse: recurrence of originally persisted
GABHS. Although serotyping of GABHS isolates helps to
make the distinction, it may be diﬃcult to distinguish
between reinfection and relapse. Holm et al. reported that
10-day cephalosporin treatment in children with recurrent
GABHS pharyngitis resulted in bacteriologic and clinical
cure rates higher than those of 10-day penicillin treatment
[18].
In this study, the recurrence rate within 3 weeks after
the initiation of therapy was signiﬁcantly higher in the 5-
day treatment group than in the 10-day treatment group.
However,thediﬀerencebetweenthe twotreatmentgroups in
rate of bacteriologic treatment failure at the follow-up visit
was not statistically signiﬁcant. All corresponding strains
isolated at pre- and posttreatments in the 24 patients with
bacteriologic treatment failure had the same serotype, indi-
cating that the treatment failure might be relapse. Only one
of the corresponding isolates in 4 children with recurrence
had diﬀerent serotypes, indicating that the treatment failure
in this case was reinfection. Test-of-cure timing, follow-
up visit in this study, is important in the interpretation of
treatment failure rate. It has been suggested that the test-
of-cure evaluation should optimally be done within 3 to 14
days after completion of therapy [12]. Although we were
not able to rule out the possibility of reinfection with a new
strain, the fact that 96% of corresponding isolates during 3-
week period had the same serotype in this study suggested
that most of the treatment failure cases within 3 weeks
were caused by relapse. Age of 6 to 7 years for boys and4 International Journal of Pediatrics
Table 2: Clinical and bacteriological results.
Results Total 5-day treatment group 10-day treatment group P value
Recurrence (clinical treatment failure) 8/226 7/77 1/149 .003
Bacteriologic treatment failure (noneradication) 24/226 7/77 17/149 .655
Treatment failure 32/226 14/77 18/149 .231
Table 3: Characteristics of children with treatment success and treatment failure.
Characteristics Treatment success group Treatment failure group P value
Number of cases 194 32
Male:Female 112 : 82 26 : 6 .011
Age (years) (mean±SD) 6.86 ±2.12 6.24 ±1.39 .036
Frequency of episodes (times) (mean±SD) 2.77 ±1.36 2.91 ±1.26 .586
Interval between preceding and present episodes (months) (mean±SD) 11.04 ±14.57 7.05 ±7.31 .018
short interval between preceding and present episodes were
associated with a signiﬁcantly higher risk of treatment failure
includingrecurrenceandbacteriologictreatmentfailure.The
frequency of episodes of recurrent GABHS pharyngitis had
no eﬀect on treatment failure.
In comparative GABHS pharyngitis antibiotic trials, it
is diﬃcult to distinguish between a GABHS carrier with an
intercurrent viral infection and a patient with acute GABHS
pharyngitis. Penicillin is not so eﬀective in eradication of
GABHS in carriers, whereas cephalosporins are eﬀective
[18]. The incidence of GABHS carriers is approximately
5t o2 0 %[ 19]. In our study, GAS carriers, if any, would
have been equally distributed in the two treatment groups.
Furthermore, to reduce the risk of enrolling GABHS carriers
with concurrent viral pharyngitis, we excluded patients with
symptoms such as rhinorrhea, cough, and conjunctivitis.
The results of a previous meta-analysis indicated that 5-
day or 10-day administration cephalosporins were superior
to 10-day administration penicillin for treatment of GABHS
pharyngitis although the results are controversial [14–
16]. There was no signiﬁcant diﬀerence between treatment
failures at the follow-up visit in the cephalosporin treatment
groups in our study. However, subsequent GABHS pharyn-
gitis within the follow-up period occurred more frequently
in the 5-day treatment group than in the 10-day treatment
group.
4. Conclusion
A 5-day course of oral cephalosporins is not always rec-
ommended for treatment of recurrent GABHS pharyngitis
in children, especially for 6- to 7-year-old boys and for
children with a short interval between preceding and present
episodes. Since this study has a limitation because of its
nonrandomized design, further studies are necessary to
determine how best to reduce treatment failure for recurrent
GABHS pharyngitis in children.
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